1
|
Bhusare N, Yadav T, Nandave M, Gadade A, Dighe V, Peters GJ, Kumar MS, Yergeri MC. Newly synthesized acridone derivatives targeting lung cancer: A toxicity and xenograft model study. Drug Dev Res 2024; 85:e22212. [PMID: 38798193 DOI: 10.1002/ddr.22212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Revised: 04/12/2024] [Accepted: 05/12/2024] [Indexed: 05/29/2024]
Abstract
AKT is one of the overexpressed targets in nonsmall cell lung cancer (NSCLC) and plays an important role in its progression and offers an attractive target for the therapy. The PI3K/AKT/mTOR pathway is upregulated in NSCLC. Acridone is an important heterocycle compound which treats cancer through various mechanisms including AKT as a target. In the present work, the study was designed to evaluate the safety profile of three acridone derivatives (AC-2, AC-7, and AC-26) by acute and repeated dose oral toxicity. In addition to this, we also checked the pAKT overexpression and its control by these derivatives in tumor xenograft model. The results from acute and repeated dose toxicity showed these compounds to be highly safe and free from any toxicity, mortality, or significant alteration in body weight, food, and water intake in the rats. In the repeated dose toxicity, compounds showed negligible variations in a few hematological parameters at 400 mg/kg. The histopathology, biochemical, and urine parameters remained unchanged. The xenograft model study demonstrated AC-2 to be inhibiting HOP-62 induced tumor via reduction in p-AKT1 (Ser473) expression significantly. In immunofluorescence staining AC-2 treated tissue section showed 2.5 fold reduction in the expression of p-AKT1 (Ser473). Histopathology studies showed the destruction of tumor cells with increased necrosis after treatment. The study concluded that AC-2 causes cell necrosis in tumor cells via blocking the p-AKT1 expression. The findings may provide a strong basis for further clinical applications of acridone derivatives in NSCLC.
Collapse
Affiliation(s)
- Nilam Bhusare
- Somaiya Institute for Research & Consultancy, Somaiya Vidyavihar University, Vidyavihar (E), Mumbai, India
| | - Tanuja Yadav
- Department of Phamaceutical Sciences, Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India
| | - Mukesh Nandave
- Department of Pharmacology, Delhi Pharmaceutical Sciences and Research Institute, New Delhi, India
| | - Amruta Gadade
- National Centre for Preclinical Reproductive & Genetic Toxicology, National Institute for Research in Reproductive and Child Health, Mumbai, India
| | - Vikas Dighe
- National Centre for Preclinical Reproductive & Genetic Toxicology, National Institute for Research in Reproductive and Child Health, Mumbai, India
| | - Godefridus J Peters
- Laboratory Medical Oncology, Amsterdam University Medical Centres, Amsterdam, The Netherlands & Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland
| | - Maushmi S Kumar
- Somaiya Institute for Research & Consultancy, Somaiya Vidyavihar University, Vidyavihar (E), Mumbai, India
| | | |
Collapse
|
2
|
Liu FC, Si MJ, Shi XR, Zhuang SY, Cai Q, Liu Y, Wu AX. Base-Controlled Synthesis of Fluorescent Acridone Derivatives via Formal (4 + 2) Cycloaddition. J Org Chem 2023. [PMID: 36780192 DOI: 10.1021/acs.joc.2c02977] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/14/2023]
Abstract
A transition-metal-free formal (4 + 2) cycloaddition for the direct assembly of acridone derivatives has been developed from simple and easily accessible o-aminobenzamides and 2-(trimethylsilyl)aryl triflates. The base played an important role in the selective controlled synthesis of N-H and N-aryl acridones. A preliminary study on the fluorescence properties of N-aryl acridones demonstrated that they could be used as fluorescent materials with a broad emission range.
Collapse
Affiliation(s)
- Fa-Chuang Liu
- Coal Conversion and New Carbon Materials Key Laboratory of Hubei Province, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, P. R. China
| | - Meng-Jie Si
- Coal Conversion and New Carbon Materials Key Laboratory of Hubei Province, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, P. R. China
| | - Xin-Ru Shi
- Coal Conversion and New Carbon Materials Key Laboratory of Hubei Province, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, P. R. China
| | - Shi-Yi Zhuang
- Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, P. R. China
| | - Qun Cai
- Coal Conversion and New Carbon Materials Key Laboratory of Hubei Province, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, P. R. China
| | - Yi Liu
- Coal Conversion and New Carbon Materials Key Laboratory of Hubei Province, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan 430081, P. R. China.,School of Chemical and Environmental Engineering, Wuhan Polytechnic University, Wuhan 430023, P. R. China
| | - An-Xin Wu
- Key Laboratory of Pesticide & Chemical Biology, Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, P. R. China
| |
Collapse
|
3
|
Alday PH, Nilsen A, Doggett JS. Structure-activity relationships of Toxoplasma gondii cytochrome bc1 inhibitors. Expert Opin Drug Discov 2022; 17:997-1011. [PMID: 35772172 PMCID: PMC9561756 DOI: 10.1080/17460441.2022.2096588] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2022] [Accepted: 06/28/2022] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Toxoplasma gondii is a prolific apicomplexan parasite that infects human and nonhuman animals worldwide and can cause severe brain and eye disease. Safer, more effective therapies for toxoplasmosis are needed. Cytochrome bc1 inhibitors are remarkably effective against toxoplasmosis and other apicomplexan-caused diseases. AREAS COVERED This work reviews T. gondii cytochrome bc1 inhibitors. Emphasis is placed on the structure-activity relationships of these inhibitors with regard to efficacy, pharmacokinetics, selectivity of T. gondii cytochrome bc1 over host, safety, and potential therapeutic strategies. EXPERT OPINION Cytochrome bc1 inhibitors are highly promising compounds for toxoplasmosis that have been effective in clinical and preclinical studies. Clinical experience with atovaquone previously validated cytochrome bc1 as a tractable drug target and, over the past decade, optimization of cytochrome bc1 inhibitors has resulted in improved bioavailability, metabolic stability, potency, blood-brain barrier penetration, and selectivity for the T. gondii cytochrome bc1 over the mammalian bc1. Recent studies have demonstrated preclinical safety, identified novel therapeutic strategies for toxoplasmosis using synergistic combinations or long-acting administration and provided insight into their role in chronic infection. This research has identified drug candidates that are more effective than clinically used drugs in preclinical measures of efficacy.
Collapse
Affiliation(s)
- Phil Holland Alday
- Portland VA Medical Center, Portland, Oregon, USA
- Oregon Health & Science University, Portland, Oregon, USA
| | - Aaron Nilsen
- Portland VA Medical Center, Portland, Oregon, USA
- Oregon Health & Science University, Portland, Oregon, USA
| | | |
Collapse
|
4
|
Wang M, Tang T, Li R, Huang Z, Ling D, Zheng L, Ding Y, Liu T, Xu W, Zhu F, Min H, Boonhok R, Mao F, Zhu J, Li X, Jiang L, Li J. Drug Repurposing of Quisinostat to Discover Novel Plasmodium falciparum HDAC1 Inhibitors with Enhanced Triple-Stage Antimalarial Activity and Improved Safety. J Med Chem 2022; 65:4156-4181. [PMID: 35175762 DOI: 10.1021/acs.jmedchem.1c01993] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Our previous work found that the clinical histone deacetylase (HDAC) inhibitor quisinostat exhibited a significant antimalarial effect but with severe toxicity. In this work, 35 novel derivatives were designed and synthesized based on quisinostat as the lead compound, and their in vitro antimalarial activities and cytotoxicities were systematically evaluated. Among them, JX35 showed potent inhibition against both wild-type and multidrug-resistant parasite strains and displayed a significant in vivo killing effect against all life cycles of parasites, including the blood stage, liver stage, and gametocyte stage, indicating its potential for the simultaneous treatment, chemoprevention, and blockage of malaria transmission. Compared with quisinostat, JX35 exhibited stronger antimalarial efficacy, more adequate safety, and good pharmacokinetic properties. Additionally, mechanistic studies via molecular docking studies, induced PfHDAC1/2 knockdown assays, and PfHDAC1 enzyme inhibition assays jointly indicated that the antimalarial target of JX35 was PfHDAC1. In summary, we discovered the promising candidate PfHDAC1 inhibitor JX35, which showed stronger triple-stage antimalarial effects and lower toxicity than quisinostat.
Collapse
Affiliation(s)
- Manjiong Wang
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Tongke Tang
- Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.,School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, P.R. China
| | - Ruoxi Li
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Zhenghui Huang
- Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China
| | - Dazheng Ling
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Lulu Zheng
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Yan Ding
- Department of Pathogenic Biology, Army Medical University, Chongqing 400038, China
| | - Taiping Liu
- Department of Pathogenic Biology, Army Medical University, Chongqing 400038, China
| | - Wenyue Xu
- Department of Pathogenic Biology, Army Medical University, Chongqing 400038, China
| | - Feng Zhu
- Division of Infectious Diseases and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612, United States
| | - Hui Min
- Division of Infectious Diseases and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612, United States
| | - Rachasak Boonhok
- Division of Infectious Diseases and International Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida 33612, United States
| | - Fei Mao
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Jin Zhu
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Xiaokang Li
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China
| | - Lubin Jiang
- Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.,School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, P.R. China
| | - Jian Li
- State Key Laboratory of Bioreactor Engineering, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.,College of Pharmacy and Chemistry, Dali University, 5 Xue Ren Road, Dali 671000, China.,Frontiers Science Center for Materiobiology and Dynamic Chemistry, East China University of Science and Technology, 130 Mei Long Road, Shanghai 200237, China
| |
Collapse
|
5
|
Kurian J, Kumari V, Chaluvalappil SV, Anas M, Manhas A, Kalluruttimmal R, Kumar N, Manheri MK. Adenine Modification at C7 as a Viable Strategy to Potentiate the Antimalarial Activity of Quinolones. ChemMedChem 2021; 17:e202100472. [PMID: 34717044 DOI: 10.1002/cmdc.202100472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/15/2021] [Indexed: 11/08/2022]
Abstract
Although many quinolones have shown promise as potent antimalarials, their clinical development has been slow due to poor performance in vivo. Insights into structural modifications that can improve their therapeutic potential will be very valuable in this vibrant area of research. Our studies involving a library of quinolones which vary in substitution pattern at N1, C3, C6 and C7 positions have shown that the presence of adenine moiety at C7 can bring a noticeable improvement in activity compared to other heterocyclic groups at this location. The most potent compound emerged from this study showed IC50 values of 0.38 μM and 0.75 μM against chloroquine-sensitive and -resistant (W2) strains, respectively. Docking analysis in the Qo site of cytochrome bc1 complex revealed the contribution of a key H-bonding interaction from the adenine unit in target binding. This corroborates with compound-induced loss of mitochondrial functions. These findings not only open avenues for further exploration of antimalarial potential of adenine-modified quinolones, but also suggests broader opportunities during lead-optimization against other antimalarial targets.
Collapse
Affiliation(s)
- Jais Kurian
- Department of Chemistry, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India
| | - Varsha Kumari
- Department of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Jankipuram extension, Sitapur road, Lucknow, 226031, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Saheer V Chaluvalappil
- Department of Chemistry, Krishna Menon Memorial Government Women's College, Kannur 670004, Kerala, India
| | - Mohammad Anas
- Department of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Jankipuram extension, Sitapur road, Lucknow, 226031, India
| | - Ashan Manhas
- Department of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Jankipuram extension, Sitapur road, Lucknow, 226031, India
| | - Ramshad Kalluruttimmal
- Department of Chemistry, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India
| | - Niti Kumar
- Department of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Sector 10, Jankipuram extension, Sitapur road, Lucknow, 226031, India.,Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India
| | - Muraleedharan K Manheri
- Department of Chemistry, Indian Institute of Technology Madras, Chennai 600036, Tamil Nadu, India
| |
Collapse
|
6
|
Moroni G, Calabria D, Quintavalla A, Lombardo M, Mirasoli M, Roda A, Gioiello A. Thermochemiluminescence‐Based Sensitive Probes: Synthesis and Photophysical Characterization of Acridine‐Containing 1,2‐Dioxetanes Focusing on Fluorophore Push‐Pull Effects. CHEMPHOTOCHEM 2021. [DOI: 10.1002/cptc.202100152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Giada Moroni
- Department of Pharmaceutical Sciences University of Perugia Via del Liceo 1 06122 Perugia Italy
- Department of Chemistry “Giacomo Ciamician” University of Bologna Via Selmi 2 40126 Bologna Italy
| | - Donato Calabria
- Department of Chemistry “Giacomo Ciamician” University of Bologna Via Selmi 2 40126 Bologna Italy
| | - Arianna Quintavalla
- Department of Chemistry “Giacomo Ciamician” University of Bologna Via Selmi 2 40126 Bologna Italy
| | - Marco Lombardo
- Department of Chemistry “Giacomo Ciamician” University of Bologna Via Selmi 2 40126 Bologna Italy
| | - Mara Mirasoli
- Department of Chemistry “Giacomo Ciamician” University of Bologna Via Selmi 2 40126 Bologna Italy
| | - Aldo Roda
- Department of Chemistry “Giacomo Ciamician” University of Bologna Via Selmi 2 40126 Bologna Italy
- National Institute of Biostructures and Biosystems (INBB) Viale delle Medaglie d'Oro 305 00136 Rome Italy
| | - Antimo Gioiello
- Department of Pharmaceutical Sciences University of Perugia Via del Liceo 1 06122 Perugia Italy
| |
Collapse
|
7
|
Tisnerat C, Dassonville-Klimpt A, Gosselet F, Sonnet P. Antimalarial drug discovery: from quinine to the most recent promising clinical drug candidates. Curr Med Chem 2021; 29:3326-3365. [PMID: 34344287 DOI: 10.2174/0929867328666210803152419] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2021] [Revised: 06/10/2021] [Accepted: 06/11/2021] [Indexed: 11/22/2022]
Abstract
Malaria is a tropical threatening disease caused by Plasmodium parasites, resulting in 409,000 deaths in 2019. The delay of mortality and morbidity has been compounded by the widespread of drug resistant parasites from Southeast Asia since two decades. The emergence of artemisinin-resistant Plasmodium in Africa, where most cases are accounted, highlights the urgent need for new medicines. In this effort, the World Health Organization and Medicines for Malaria Venture joined to define clear goals for novel therapies and characterized the target candidate profile. This ongoing search for new treatments is based on imperative labor in medicinal chemistry which is summarized here with particular attention to hit-to-lead optimizations, key properties, and modes of action of these novel antimalarial drugs. This review, after presenting the current antimalarial chemotherapy, from quinine to the latest marketed drugs, focuses in particular on recent advances of the most promising antimalarial candidates in clinical and preclinical phases.
Collapse
Affiliation(s)
- Camille Tisnerat
- AGIR UR4294, UFR de Pharmacie, Université de Picardie Jules Verne, Amiens. France
| | | | | | - Pascal Sonnet
- AGIR UR4294, UFR de Pharmacie, Université de Picardie Jules Verne, Amiens. France
| |
Collapse
|
8
|
Alday PH, McConnell EV, Boitz Zarella JM, Dodean RA, Kancharla P, Kelly JX, Doggett JS. Acridones Are Highly Potent Inhibitors of Toxoplasma gondii Tachyzoites. ACS Infect Dis 2021; 7:1877-1884. [PMID: 33723998 DOI: 10.1021/acsinfecdis.1c00016] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Acridone derivatives, which have been shown to have in vitro and in vivo activity against Plasmodium spp, inhibit Toxoplasma gondii proliferation at picomolar concentrations. Using enzymatic assays, we show that acridones inhibit both T. gondii cytochrome bc1 and dihydroorotate dehydrogenase and identify acridones that bind preferentially to the Qi site of cytochrome bc1. We identify acridones that have efficacy in a murine model of systemic toxoplasmosis. Acridones have potent activity against T. gondii and represent a promising new class of preclinical compounds.
Collapse
Affiliation(s)
- P. Holland Alday
- Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States
| | - Erin V. McConnell
- Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States
| | - Jan M. Boitz Zarella
- Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States
| | - Rozalia A. Dodean
- Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States
| | - Papireddy Kancharla
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
| | - Jane X. Kelly
- Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
| | - J. Stone Doggett
- Portland VA Medical Center, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States
| |
Collapse
|
9
|
Li H, Song B, Mahmut M, Imerhasan M. One-Pot Green Synthesis of Acridine Alkaloid Derivatives and Screening of in vitro Anti-cancer Activity Against Cdc25b and SHP1. Curr Org Synth 2020; 18:399-405. [PMID: 33371849 DOI: 10.2174/1570179417666201228165500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Revised: 10/24/2020] [Accepted: 10/26/2020] [Indexed: 11/22/2022]
Abstract
AIM To develop anti-cancer active pharmaceutical intermediates. BACKGROUND Acridone derivatives possess a wide range of pharmacological activities: 1) they intercalate DNA and 2) form a covalent bond with DNA. OBJECTIVE To screen in vitro anti-cancer activity against Cdc25b and SHP1 of new acridone derivatives and preliminary study on the structure-activity relationship. MATERIALS AND METHODS The synthesis of new acridone derivatives and in vitro evaluation of their anti-cancer activity on Cdc25b and SHP1 was achieved. Natural products that contain acridine structures, such as cystodytin A and acronycine, are isolated from certain marine (tunicates & ascidians, sponges, sea anemones) and plant (bark of Australian scrub ash tree) species. Herein, we report the efficient one-pot green synthesis of twelve novel 3,4-dihydro-1 (2H) acridone derivatives, using montmorillonite K10 as the catalyst and iron/citric acid in water. Also, their inhibitory activity against Cdc25B and SHP1 is examined, in which specific derivatives show enhanced inhibitory activity compared to others. RESULTS AND DISCUSSION Twelve new acridone derivatives were prepared, starting from 2-nitrobenzaldehyde derivatives and 1, 3-cyclohexanedione derivatives, which exhibited substantial anti-cancer activity against Cdc25b and SHP1 cells. CONCLUSION Preliminary studies on the structure-activity relationship have shown the influence of the structural parameters and, in particular, the nature of the substituent on aromatic ring structure and cyclohexanone. Other: Further study on the structure-activity relationship is required.
Collapse
Affiliation(s)
- Hao Li
- Key Laboratory of Energy Materials Chemistry, Ministry of Education; Key Laboratory of Advanced Functional Materials, Autonomous Region; Institute of Applied Chemistry, Urumqi Key Laboratory of Green Catalysis and Synthesis Technology, College of Chemistry, Xinjiang University, Urumqi, 830046, Xinjiang, China
| | - Buer Song
- Key Laboratory of Plant Resources and Chemistry in Arid Regions, Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Science, Urumqi, 830011, Xinjiang, China
| | - Mamtimin Mahmut
- Key Laboratory of Energy Materials Chemistry, Ministry of Education; Key Laboratory of Advanced Functional Materials, Autonomous Region; Institute of Applied Chemistry, Urumqi Key Laboratory of Green Catalysis and Synthesis Technology, College of Chemistry, Xinjiang University, Urumqi, 830046, Xinjiang, China
| | - Mukhtar Imerhasan
- Key Laboratory of Energy Materials Chemistry, Ministry of Education; Key Laboratory of Advanced Functional Materials, Autonomous Region; Institute of Applied Chemistry, Urumqi Key Laboratory of Green Catalysis and Synthesis Technology, College of Chemistry, Xinjiang University, Urumqi, 830046, Xinjiang, China
| |
Collapse
|
10
|
Veligeti R, Madhu RB, Anireddy J, Pasupuleti VR, Avula VKR, Ethiraj KS, Uppalanchi S, Kasturi S, Perumal Y, Anantaraju HS, Polkam N, Guda MR, Vallela S, Zyryanov GV. Synthesis of novel cytotoxic tetracyclic acridone derivatives and study of their molecular docking, ADMET, QSAR, bioactivity and protein binding properties. Sci Rep 2020; 10:20720. [PMID: 33244007 PMCID: PMC7691360 DOI: 10.1038/s41598-020-77590-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Accepted: 11/12/2020] [Indexed: 11/09/2022] Open
Abstract
Acridone based synthetic and natural products with inherent anticancer activity advancing the research and generating a large number of structurally diversified compounds. In this sequence we have designed, synthesized a series of tetracyclic acridones with amide framework viz., 3-(alkyloyl/ aryloyl/ heteroaryloyl/ heteroaryl)-2,3-dihydropyrazino[3,2,1-de]acridin-7(1H)-ones and screened for their in vitro anti-cancer activity. The in vitro study revealed that compounds with cyclopropyl-acetyl, benzoyl, p-hydroxybenzoyl, p-(trifluoromethyl)benzoyl, p-fluorobenzoyl, m-fluorobenzoyl, picolinoyl, 6-methylpicolinoyl and 3-nicotinoyl groups are active against HT29, MDAMB231 and HEK293T cancer cell lines. The molecular docking studies performed for them against 4N5Y, HT29 and 2VWD revealed the potential ligand-protein binding interactions among the neutral aminoacid of the enzymes and carbonyl groups of the title compounds with a binding energy ranging from - 8.1394 to - 6.9915 kcal/mol. In addition, the BSA protein binding assay performed for them has confirmed their interaction with target proteins through strong binding to BSA macromolecule. The additional studies like ADMET, QSAR, bioactivity scores, drug properties and toxicity risks ascertained them as newer drug candidates. This study had added a new collection of piperazino fused acridone derivatives to the existing array of other nitrogen heterocyclic fused acridone derivatives as anticancer agents.
Collapse
Affiliation(s)
- Rajkumar Veligeti
- Centre for Chemical Sciences and Technology, Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Hyderabad, Telangana, 500085, India.,Medicinal Chemistry Division, GVK Biosciences Private Limited, Plot No. 28A, IDA Nacharam, Hyderabad, Telangana, 500076, India
| | - Rajesh Bagepalli Madhu
- Medicinal Chemistry Division, GVK Biosciences Private Limited, Plot No. 28A, IDA Nacharam, Hyderabad, Telangana, 500076, India. .,Discovery and Development Solutions, GVK Biosciences Private Limited, Plot No. 284A, Jigini Village, Bengaluru, Karnataka, 562106, India.
| | - Jayashree Anireddy
- Centre for Chemical Sciences and Technology, Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Hyderabad, Telangana, 500085, India.
| | - Visweswara Rao Pasupuleti
- Department of Biomedical Sciences and Therapeutics, Faculty of Medicine and Health Sciences, Universiti Malaysia Sabah, 88400, Kota Kinabalu, Sabah, Malaysia.
| | - Vijaya Kumar Reddy Avula
- Chemical Engineering Institute, Ural Federal University, Yekaterinburg, Russian Federation, 620002.
| | - Krishna S Ethiraj
- Medicinal Chemistry Division, GVK Biosciences Private Limited, Plot No. 28A, IDA Nacharam, Hyderabad, Telangana, 500076, India
| | - Srinivas Uppalanchi
- Medicinal Chemistry Division, GVK Biosciences Private Limited, Plot No. 28A, IDA Nacharam, Hyderabad, Telangana, 500076, India
| | - Sivaprasad Kasturi
- Centre for Chemical Sciences and Technology, Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Hyderabad, Telangana, 500085, India.,Medicinal Chemistry Division, GVK Biosciences Private Limited, Plot No. 28A, IDA Nacharam, Hyderabad, Telangana, 500076, India
| | - Yogeeswari Perumal
- Drug Discovery Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science - Pilani, Hyderabad Campus, Hyderabad, Telangana, 500078, India
| | - Hasitha Shilpa Anantaraju
- Drug Discovery Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science - Pilani, Hyderabad Campus, Hyderabad, Telangana, 500078, India
| | - Naveen Polkam
- Centre for Chemical Sciences and Technology, Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Hyderabad, Telangana, 500085, India
| | - Mallilkarjuna Reddy Guda
- Chemical Engineering Institute, Ural Federal University, Yekaterinburg, Russian Federation, 620002
| | - Swetha Vallela
- Chemical Engineering Institute, Ural Federal University, Yekaterinburg, Russian Federation, 620002
| | - Grigory Vasilievich Zyryanov
- Chemical Engineering Institute, Ural Federal University, Yekaterinburg, Russian Federation, 620002.,Ural Division of the Russian Academy of Sciences, I. Ya. Postovskiy Institute of Organic Synthesis, 22 S. Kovalevskoy Street, Yekaterinburg, Russian Federation, 620219
| |
Collapse
|
11
|
Kancharla P, Dodean RA, Li Y, Pou S, Pybus B, Melendez V, Read L, Bane CE, Vesely B, Kreishman-Deitrick M, Black C, Li Q, Sciotti RJ, Olmeda R, Luong TL, Gaona H, Potter B, Sousa J, Marcsisin S, Caridha D, Xie L, Vuong C, Zeng Q, Zhang J, Zhang P, Lin H, Butler K, Roncal N, Gaynor-Ohnstad L, Leed SE, Nolan C, Ceja FG, Rasmussen SA, Tumwebaze PK, Rosenthal PJ, Mu J, Bayles BR, Cooper RA, Reynolds KA, Smilkstein MJ, Riscoe MK, Kelly JX. Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials. J Med Chem 2020; 63:6179-6202. [PMID: 32390431 PMCID: PMC7354843 DOI: 10.1021/acs.jmedchem.0c00539] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
The global impact of malaria remains staggering despite extensive efforts to eradicate the disease. With increasing drug resistance and the absence of a clinically available vaccine, there is an urgent need for novel, affordable, and safe drugs for prevention and treatment of malaria. Previously, we described a novel antimalarial acridone chemotype that is potent against both blood-stage and liver-stage malaria parasites. Here, we describe an optimization process that has produced a second-generation acridone series with significant improvements in efficacy, metabolic stability, pharmacokinetics, and safety profiles. These findings highlight the therapeutic potential of dual-stage targeting acridones as novel drug candidates for further preclinical development.
Collapse
Affiliation(s)
- Papireddy Kancharla
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
| | - Rozalia A. Dodean
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Yuexin Li
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Sovitj Pou
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Brandon Pybus
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Victor Melendez
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Lisa Read
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Charles E. Bane
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Brian Vesely
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Mara Kreishman-Deitrick
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Chad Black
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Qigui Li
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Richard J. Sciotti
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Raul Olmeda
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Thu-Lan Luong
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Heather Gaona
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Brittney Potter
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Jason Sousa
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Sean Marcsisin
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Diana Caridha
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Lisa Xie
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Chau Vuong
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Qiang Zeng
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Jing Zhang
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Ping Zhang
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Hsiuling Lin
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Kirk Butler
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Norma Roncal
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Lacy Gaynor-Ohnstad
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Susan E. Leed
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Christina Nolan
- Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States
| | - Frida G. Ceja
- Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, United States
| | - Stephanie A. Rasmussen
- Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, United States
| | | | - Philip J. Rosenthal
- Department of Medicine, University of California, San Francisco, CA 94143, United States
| | - Jianbing Mu
- Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville MD 20852, USA
| | - Brett R. Bayles
- Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, United States
- Global Public Health Program, Dominican University of California, San Rafael CA 94901
| | - Roland A. Cooper
- Department of Natural Sciences and Mathematics, Dominican University of California, San Rafael, CA 94901, United States
| | - Kevin A. Reynolds
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
| | - Martin J. Smilkstein
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Michael K. Riscoe
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Jane X. Kelly
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| |
Collapse
|
12
|
Zhang L, Yang W, Hu Z, Zhang X, Xu X. Tandem Access to Acridones and their Fused Derivatives: [1+2+3] Annulation of Isocyanides with Unsaturated Carbonyls. Adv Synth Catal 2020. [DOI: 10.1002/adsc.201901560] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Ling‐Juan Zhang
- Key Laboratory of Magnetic Molecules & Magnetic Information Materials (Ministry of Education), School of Chemistry & Material ScienceShanxi Normal University, Linfen Shanxi 041004 People's Republic of China
| | - Wenhui Yang
- Key Laboratory of Magnetic Molecules & Magnetic Information Materials (Ministry of Education), School of Chemistry & Material ScienceShanxi Normal University, Linfen Shanxi 041004 People's Republic of China
| | - Zhongyan Hu
- College of Chemistry, Chemical Engineering and Materials Science, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Institute of Molecular and Nano ScienceShandong Normal University Jinan 250014 People's Republic of China
| | - Xian‐Ming Zhang
- Key Laboratory of Magnetic Molecules & Magnetic Information Materials (Ministry of Education), School of Chemistry & Material ScienceShanxi Normal University, Linfen Shanxi 041004 People's Republic of China
| | - Xianxiu Xu
- College of Chemistry, Chemical Engineering and Materials Science, Collaborative Innovation Center of Functionalized Probes for Chemical Imaging in Universities of Shandong, Key Laboratory of Molecular and Nano Probes, Ministry of Education, Institute of Molecular and Nano ScienceShandong Normal University Jinan 250014 People's Republic of China
| |
Collapse
|
13
|
Kancharla P, Dodean RA, Li Y, Kelly JX. Boron Trifluoride Etherate Promoted Microwave-Assisted Synthesis of Antimalarial Acridones. RSC Adv 2019; 9:42284-42293. [PMID: 35321096 PMCID: PMC8939876 DOI: 10.1039/c9ra09478d] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
A microwave-assisted, rapid and efficient method using boron trifluoride etherate (BF3.Et2O) for the synthesis of acridones, via an intramolecular acylation of N-phenylanthranilic acid derivatives, has been developed. The reaction proceeds under solvent-free conditions, tolerates a wide range of functional groups, and provides rapid access to a range of acridones in good to excellent yields. Several of the synthesized acridones exhibited potent antimalarial activities against CQ sensitive and multi-drug resistant (MDR) parasites.
Collapse
Affiliation(s)
- Papireddy Kancharla
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States
| | - Rozalia A Dodean
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States.,Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Yuexin Li
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States.,Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| | - Jane X Kelly
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States.,Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States
| |
Collapse
|